Fermentation and cardiovascular risk factors

| Submission date | Recruitment status | Prospectively registered | | |
|-------------------|-----------------------------------|--|--|--|
| 07/06/2007 | No longer recruiting | ☐ Protocol | | |
| Registration date | Overall study status | Statistical analysis plan | | |
| 02/08/2007 | Completed | [X] Results | | |
| Last Edited | Condition category | Individual participant data | | |
| 07/02/2012 | Nutritional. Metabolic. Endocrine | | | |

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Denise Robertson

Contact details

Biomedical and Molecular Sciences University of Surrey Guildford United Kingdom GU2 7XH

Additional identifiers

EudraCT/CTIS number

IRAS number

 ${\bf Clinical Trials. gov\ number}$

Secondary identifying numbers

NS1

Study information

Scientific Title

Study objectives

That consuming a fermentable carbohydrate will improve indices of insulin sensitivity in individuals with insulin resistance.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Central Office of Research Ethics Committees (COREC) and the University of Surrey Ethics Committee, approved on 26th June 2006 (REC ref: O6/Q1909/30)

Study design

Randomised, parallel, single-blind dietary intervention.

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Type 2 diabetes/ obesity

Interventions

Dietary supplementation with either 0 g, 20 g or 40 g resistant starch per day for 12 weeks.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

resistant starch

Primary outcome measure

Insulin sensitivity will be assessed before and after the 12-week intervention by the following:

- 1. Euglycaemic-hyperinsulinaemic clamp
- 2. Liver fat content measured by Magnetic Resonance Imaging [MRI]

Secondary outcome measures

The following outcomes are being measured before and after the 12-week intervention:

- 1. Endothelial function, assessed by Pulse Wave Velocity (PWV) and 24-hour blood pressure recordings
- 2. Blood inflammatory markers

Overall study start date

01/11/2006

Completion date

30/10/2008

Eligibility

Key inclusion criteria

- 1. Healthy
- 2. Fasting insulin >60 pmol/l
- 2. Male and female 18-60 years

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Upper age limit

60 Years

Sex

Both

Target number of participants

45

Key exclusion criteria

- 1. Cardiovascular or endocrine diseases
- 2. Medication likely to affects either lipid or glucose metabolism

Date of first enrolment

01/11/2006

Date of final enrolment

30/10/2008

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
Biomedical and Molecular Sciences
Guildford
United Kingdom
GU2 7XH

Sponsor information

Organisation

University of Surrey (UK)

Sponsor details

Research and Enterprise Support Nodus Centre University of Surrey Guildford England United Kingdom GU2 7XH

Sponsor type

University/education

Website

http://www.surrey.ac.uk/

ROR

https://ror.org/00ks66431

Funder(s)

Funder type

Industry

Funder Name

National Starch and Chemical Company (International)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|-----------------|---------|--------------|------------|----------------|-----------------|
| Results article | results | 01/04/2010 | | Yes | No |